Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer

Author:
  • Donal Brennan
  • Sara Ek
  • Emma Doyle
  • Thomas Drew
  • Michael Foley
  • Grainne Flannelly
  • Darren P O´Conner
  • William M Gallagher
  • Sami Kilpinen
  • Olli-Pekka Kallioniemi
  • Karin Jirström
  • Colm O'Herlihy
  • Carl Borrebaeck
Publishing year: 2009
Language: English
Pages: 1510-1517
Publication/Series: European Journal of Cancer
Volume: 45
Issue: 8
Document type: Journal article
Publisher: IFAC & Elsevier Ltd.

Abstract english

Abstract

Background:

Current prognostic molecular markers for epithelial ovarian cancer (EOC) are

insufficient. The aim of the current study was to investigate the role of Sox11 in EOC

Methods:

Using an in silico transcriptomic screen Sox11 was identified as a potential EOC

biomarker. Sox11 protein expression was evaluated using immunohistochemistry (IHC)

in 76 EOC cases, which were analyzed using automated algorithms to develop a

quantitative scoring model.

Results:

Sox11 mRNA expression was up-regulated in EOC compared to normal tissues.

Automated analysis of Sox11 in the EOC cohort revealed high expression of Sox11, in

40% of tumours, who had an improved recurrence free survival (RFS) (p= 0.002).

Multivariate analysis confirmed Sox11 was an independent predictor of improved RFS

after controlling for stage and grade.

Conclusions:

These data suggest that Sox11 is a new prognostic marker in EOC. Loss of SOX 11 is

associated with a decreased RFS and a more aggressive phenotype.

Keywords

  • Immunology in the medical area

Other

Published
  • CREATE Health
  • ISSN: 1879-0852
Carl Borrebaeck
E-mail: carl [dot] borrebaeck [at] immun [dot] lth [dot] se

Professor

Department of Immunotechnology

313k1

90

Director

Create Health

+46 46 222 96 13

313k1

90